MDRNA Aims to Market Cequent FAP Drug, File Three INDs by 2011

"We believe [the FAP drug] is a product that the combined company could commercialize with a small specialty sales force [with] minimal sales and marketing infrastructure," MDRNA's President and CEO Michael French said this week.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.